Most ischemic events in patients with coronary artery disease, peripheral artery disease, or
cerebrovascular disease result from thrombosis or embolism arising from disrupted …

Until recently, attempts to improve the benefit of aspirin by adding another antithrombotic
agent have not resulted in a mortality reduction in patients with chronic symptomatic …

Atherosclerosis is a multifactorial vascular disease that develops in the course of a lifetime.
Numerous risk factors for atherosclerosis have been identified, mostly infiicting pro …

The persisting risk of cardiovascular disease (CVD) events despite reaching targets for
known CVD risk factor such as low density lipoprotein (LDL) cholesterol, blood pressure …

BACKGROUND: We evaluated whether rivaroxaban alone or in combination with aspirin
would be more effective than aspirin alone for secondary cardiovascular prevention …

Background The combination of 2.5 mg rivaroxaban twice daily and 100 mg aspirin once
daily compared with 100 mg aspirin once daily reduces major adverse cardiovascular (CV) …

Thrombosis is a major contributor to the adverse outcomes associated with atherosclerotic
disease. Acute coronary syndromes (ACS) result when intravascular thrombosis occurs at …

Intensifying antiplatelet therapy (ie, using a dual antiplatelet therapy with aspirin plus a
P2Y12 inhibitor), using additional prevention medication (eg, statins or other lipid-lowering …

Long-term management of atherothrombosis Page 1 SYMPOSIUM ON CHRONIC DISEASE
MANAGEMENT Keith AA Fox Atherothrombosis and its complica- tions (myocardial infarction …

The COMPASS trial compared the impact of the selective direct factor Xa inhibitor,
rivaroxaban, as monotherapy or in combination with aspirin on major adverse …